BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33878394)

  • 21. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
    Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
    Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer.
    Schinke H; Shi E; Lin Z; Quadt T; Kranz G; Zhou J; Wang H; Hess J; Heuer S; Belka C; Zitzelsberger H; Schumacher U; Genduso S; Riecken K; Gao Y; Wu Z; Reichel CA; Walz C; Canis M; Unger K; Baumeister P; Pan M; Gires O
    Mol Cancer; 2022 Sep; 21(1):178. PubMed ID: 36076232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
    Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.
    Karamboulas C; Bruce JP; Hope AJ; Meens J; Huang SH; Erdmann N; Hyatt E; Pereira K; Goldstein DP; Weinreb I; Su J; O'Sullivan B; Tiedemann R; Liu FF; Pugh TJ; Bratman SV; Xu W; Ailles L
    Cell Rep; 2018 Oct; 25(5):1318-1331.e4. PubMed ID: 30380421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.
    Dosil MA; Mirantes C; Eritja N; Felip I; Navaridas R; Gatius S; Santacana M; Colàs E; Moiola C; Schoenenberger JA; Encinas M; Garí E; Matias-Guiu X; Dolcet X
    J Pathol; 2017 Jun; 242(2):152-164. PubMed ID: 28349562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
    Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
    Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
    Goel S; Wang Q; Watt AC; Tolaney SM; Dillon DA; Li W; Ramm S; Palmer AC; Yuzugullu H; Varadan V; Tuck D; Harris LN; Wong KK; Liu XS; Sicinski P; Winer EP; Krop IE; Zhao JJ
    Cancer Cell; 2016 Mar; 29(3):255-269. PubMed ID: 26977878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
    Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
    Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
    Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
    Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
    Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana.
    Owusu-Afriyie O; Owiredu WKBA; Owusu-Danquah K; Komarck C; Foltin SK; Larsen-Reindorf R; Acheampong E; Quayson SE; Prince MEP; McHugh JB; Donkor P; Merajver SD; Brenner JC
    PLoS One; 2018; 13(8):e0202790. PubMed ID: 30138436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and Biological Evaluation of Novel
    Song X; Gan Q; Zhang X; Zhang J
    Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.